Clinical Trials Logo
  1. Home
  2. COPD Patients
  3. NCT00180622
  4. Details
NCT00180622 Clinical Trial

Markers for Chronic Obstructive Pulmonary Disease (COPD)

COPD Patients Clinical Trial

Official title:
Non-Invasive Markers for Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00180622
Other study ID # SD-000-068
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date July 1, 2001
Est. completion date July 1, 2002

Study information
Verified date July 2019
Source Imperial College London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date July 1, 2002
Est. primary completion date July 1, 2002
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

Healthy non-smokers

- FEV1 >80% predicted

- FEV1 reversibility of <10% after inhaled (beta2-agonists

Current smokers

- FEV1 no less than 80% predicted

- FEV1 reversibility of <10% after inhaled (beta2-agonists

- Smoking history of > 10 pack-years

Moderate COPD

- FEV1 40-59% predicted

- FEV1 reversibility of <10% after inhaled (beta2-agonists

- Smoking history of > 10 pack-years**

Severe COPD

- FEV1 <40% predicted

- FEV1 reversibility of <10% after inhaled (beta2-agonists

- Smoking history of > 10 pack-years

Exclusion Criteria:

- FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists

- Asthma

- unstable disease (FEV1 <35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Spirometry

• Exhaled Nitric Oxide and Carbon Monoxide

• Exhaled Breath Condensate

• Induced Sputum

• CT Scan

• Blood test

• St Georges Questionnaire

• Bodypletysmography

Locations
Country Name City State
United Kingdom Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital London

Sponsors (2)
Lead Sponsor Collaborator
Imperial College London AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05980611 - Nasal IL 1 Beta ,IL 3 Level and Their Effects in COPD Patients
Recruiting NCT00949195 - Pulmonary Arterial Pressure Response During Exercise N/A
Completed NCT06128902 - The Effect of Home-Based Monitoring, Exercise Training N/A
Completed NCT01475812 - Daily Activities Are Sufficient to Induce Dynamic Pulmonary Hyperinflation and Dyspnea in Chronic Obstructive Pulmonary Disease Patients N/A
Completed NCT02157935 - Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease Phase 3
Completed NCT01183052 - Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients N/A
Completed NCT04869033 - Effects of Farinelli's Breathing Exercise in COPD Patients N/A
Completed NCT02099279 - Prognostic Value Cardiac Dysfunction Assessed by Bedside Echocardiography in Critically Ill COPD Patients Requiring Mechanical Ventilation N/A
Withdrawn NCT00361426 - EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients N/A
Recruiting NCT03774238 - Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients N/A
Enrolling by invitation NCT03851991 - The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. Phase 4